Apremilast, a PDE-4 inhibitor used in psoriasis and psoriatic arthritis (37), demonstrates a notable incidence of headache, particularly in the first two months of treatment, though symptoms often diminish over time (38). This evidence concerns the gene PDE4A and psoriatic arthritis.